Real-world diagnostic performance of blood-based biomarkers for Alzheimer’s disease: robust performance except after stroke and high charlson comorbidity index | Synapse
February 8, 2026Open Access
Real-world diagnostic performance of blood-based biomarkers for Alzheimer’s disease: robust performance except after stroke and high charlson comorbidity index
Key Points
To evaluate the diagnostic performance of blood-based biomarkers for Alzheimer's disease in real-world settings.
Evaluated various blood-based biomarkers for Alzheimer’s disease diagnosis.
Assessed patient outcomes in relation to stroke and Charlson Comorbidity Index (CCI).
Analyzed performance metrics of biomarkers across different patient factors.
Blood-based biomarkers showed overall robust performance for Alzheimer's diagnosis.
Performance was notably less effective in patients with a history of stroke.
High Charlson Comorbidity Index (CCI) also indicated a need for caution in diagnosis.
Abstract
Overall, patient factors had limited impact on biomarkers, but caution is needed for patients with stroke or high CCI.